86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

62 trials found

diseases per page:

Showing 1 to 10 of 62 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04972656 (ClinicalTrials.gov)	March 5, 2022	9/7/2021	Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension	Treatment With Ambrisentanin Patients With Borderline Pulmonary Arterial Hypertension: a Multicenter ...	Pulmonary Arterial Hypertension	Drug: Ambrisentan;Drug: Placebo	Nanjing First Hospital, Nanjing Medical University	Tianjin Medical University General Hospital	Not yet recruiting	18 Years	N/A	All	420	N/A	NULL
2	NCT04528056 (ClinicalTrials.gov)	August 1, 2020	14/8/2020	Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension	Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Sulfasalazine;Drug: Ambrisentan;Drug: Sulfasalazine's placebo;Drug: Ambrisentan's placebo	RenJi Hospital	NULL	Recruiting	18 Years	75 Years	All	80	Phase 1/Phase 2	China
3	EUCTR2019-001699-12-GB (EUCTR)	27/08/2019	30/07/2019	Relative bioavailability study of marketed and lower dose ambrisentan in healthy adult participants	An open-label, randomized three period cross-over relative bioavailability study to compare the phar ...	Pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ...	Product Name: Ambrisentan Tablet Product Code: GSK1325760 INN or Proposed INN: AMBRISENTAN Other descrip ...	GlaxoSmithKline Research and Development Ltd	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 1	United Kingdom
4	NCT02999906 (ClinicalTrials.gov)	October 2017	19/12/2016	Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (A ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy ...	Pulmonary Arterial Hypertension	Drug: Oral Treprostinil;Drug: Placebo	United Therapeutics	NULL	Withdrawn	18 Years	79 Years	All	0	Phase 3	NULL
5	NCT02885012 (ClinicalTrials.gov)	June 2016	3/5/2016	Crossover Study From Macitentan or Bosentan Over to Ambrisentan	A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan(Let ...	Pulmonary Arterial Hypertension	Drug: Ambrisentan	Medical University of South Carolina	Ochsner Health System	Terminated	18 Years	80 Years	All	3	Phase 4	United States
6	NCT03809156 (ClinicalTrials.gov)	April 26, 2016	9/1/2019	Upfront Combination Pulmonary Arterial Hypertension Therapy	Upfront Riociguat and AmbrisentanCombination Therapy for Pulmonary Arterial Hypertension: A Safety a ...	Pulmonary Hypertension	Drug: Riociguat Oral Product	University of Calgary	Bayer	Recruiting	18 Years	N/A	All	20	Phase 4	Canada
7	NCT02253394 (ClinicalTrials.gov)	September 2015	17/9/2014	The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study	The Combination AmbrisentanPlus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PA ...	Pulmonary Arterial Hypertension	Drug: Ambrisentan plus Spironolactone;Drug: Ambrisentan plus Placebo	Brigham and Women's Hospital	Gilead Sciences	Terminated	18 Years	N/A	All	2	Phase 4	United States
8	ChiCTR-OON-17013521	2015-02-01	2017-11-24	Transition from ambrisentanto bosentan in pulmonary arterial hypertension: A single center prospecti ...	Transition from ambrisentanto bosentan in pulmonary arterial hypertension: A single center prospecti ...	pulmonary arterial hypertension	ambrisentan group:oral ambrisentan;bosentan group:oral bosentan;	Shanghai Pulmonary Hospital	NULL	Completed			Male	ambrisentan group:12;bosentan group:8;		China
9	EUCTR2014-001882-28-DE (EUCTR)	13/10/2014	07/08/2014	Drug treatment of patients with systemic sclerosis to prevent deterioration of pulmonary hypertensio ...	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SS ...	Systemic sclerosis-patients (SSc) with borderline pulmonary arterial hypertension;Therapeutic area: ...	Trade Name: Volibris Product Name: Ambrisentan	Thoraxklinik-Heidelberg gGmbH	NULL	Not Recruiting			Female: yes Male: yes	38	Phase 2	Germany
10	NCT02290613 (ClinicalTrials.gov)	July 1, 2014	31/10/2014	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SS ...	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SS ...	Systemic Sclerosis;Pulmonary Hypertension	Drug: Ambrisentan;Drug: Placebo	Heidelberg University	GlaxoSmithKline	Completed	18 Years	N/A	All	38	Phase 2	Germany

First Previous1 2 3 4 5 6 7Next Last